INTERNATIONAL PATENT: GENMAB A/S, MSD INTERNATIONAL BUSINESS GMBH, BIONTECH SE FILES APPLICATION FOR "BISPECIFIC ANTIBODY AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY"

GENEVA, Dec. 1 -- GENMAB A/S (Carl Jacobsens Vej 30DK-2500 Valby), MSD INTERNATIONAL BUSINESS GMBH (Tribschenstrasse 606005 Luzern), BIONTECH SE (An der Goldgrube 1255131 Mainz) filed a patent application (PCT/EP2025/064194) for "BISPECIFIC ANTIBODY AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY" on May 22, 2025. With publication no. WO/2025/242827, the details related to the patent application was published on Nov 27, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ONG, Teng Jin (c/o Genmab US, Inc.777 Scudders Mill RoadPlainsboro, New Jersey 08536), AHMADI, Tahamtan (c/o Genmab US, Inc.777...